• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cordis acquires drug-eluting balloon maker MedAlliance for up to $1.135B

October 2, 2023 By Sean Whooley

MedAlliance SELUTION SLRMedAlliance announced today that Cordis acquired it for a total consideration that could reach up to $1.135 billion.

The companies initially announced the planned deal in October of last year.

Cordis, which develops interventional cardiovascular and endovascular technologies, made a $35 million investment last year. Its upfront closing payment totals $200 million, with achievement milestones reaching up to $125 million. With up to $775 million available in commercial milestones through 2029, the total consideration comes to $1.135 billion.

MedAlliance develops the Selution SLR sustained sirolimus drug-eluting balloon program. The company said its product family complements Cordis’ existing product portfolio along with its sales, marketing and distribution expertise.

Selution SLR provides a controlled sustained drug release, similar to a drug-eluting stent. It features unique micro-reservoirs made of biodegradable polymer intermixed with sirolimus. The micro-reservoirs provide a controlled and permanent release of the drug for up to 90 days. MedAlliance’s CAT (cell-adherent technology) allows microdeposits to coat the balloons and adhere to the vessel lumen when delivered through an angioplasty balloon.

Geneva, Switzerland-based MedAlliance has achieved a range of regulatory milestones to date. It first earned CE mark for treating peripheral artery disease in February 2020, then coronary artery disease in May 2020.

MedAlliance received its first FDA investigational device exemption (IDE) for Selution SLR in below-the-knee indications in May 2022. It picked up a second IDE in August. Those regulatory nods cover occlusive disease of the superficial femoral artery (SFA) and coronary in-stent restenosis (ISR). Another IDE came in January for the treatment of coronary de novo lesions.

The balloon is commercially available in Europe, Asia, the Middle East and the Americas outside the U.S.

Executives comment on the Cordis acquisition of MedAlliance

Jeffrey B. Jump, MedAlliance founder, chair and CEO said the acquisition can accelerate access to the company’s technology.

“I want to thank our entire MedAlliance team – including physicians, distributors and clinical patients – who have succeeded in disrupting the coronary and peripheral markets to provide a safe and effective new technology,” Jump said. “The arsenal of Selution SLR DEB clinical data is designed to change medical practice and improve patient outcomes.”

Shar Matin, Cordis CEO, noted that the company introduced its Cypher drug-eluting stent nearly 20 years ago. Matin said that transformed cardiovascular treatment for patients around the world.

“As a newly independent company, we are beyond proud to further our legacy of innovation and market disruption with MedAlliance and the first MicroReservoir sirolimus drug-eluting balloon, Selution SLR,” Matin said.

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Mergers & Acquisitions, Vascular Tagged With: cordis, MedAlliance

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS